• Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Scanfil Q2'26 preview: Growth engine has been running on two cylinders

SCANFLAnalyst Comment13.07.2026, 07.56
Antti ViljakainenHead of Research
Discuss

Summary

  • Scanfil's Q2 revenue is expected to have grown by over 25% year-on-year to 254 MEUR, primarily driven by acquisitions, with organic growth contributing around 6%.
  • Adjusted EBITA is forecasted to have increased by 29% to 18.4 MEUR, supported by strong revenue growth and improved capacity utilization, though new project ramp-ups may limit margin expansion.
  • Scanfil is anticipated to reiterate its guidance for the current year, with revenue projected between 940–1,060 MEUR and adjusted EBITA between 64–78 MEUR, aligning closely with Inderes' estimates.
  • Despite strong performance, Scanfil's valuation appears elevated, with a P/E of 17x and EV/EBITA of 13x for 2026e, suggesting that further share price increases would require positive updates on organic growth prospects.

This content is generated by AI. You can give feedback on it in the Inderes forum.

Estimates Q2'25 Q2'26 Q2'26e Q2'26e 2026e
MEUR/EUR Comparison Actualized Inderes Consensus Inderes
Revenue 202.2   253.7   993.1
EBITA (adj.) 14.2   18.4   72.6
EBIT 13.3   17.4   68.2
Profit before tax 13.5   16.3   63.8
EPS (reported) 0.16   0.19   0.73
           
Revenue growth-% 3.4%   25.4%   24.6%
EBITA-% (adj.) 7.0%   7.2%   7.3%

Source: Inderes

Translation: Original published in Finnish on 7/13/2026 at 7:30 am EEST.

Scanfil will publish its Q2 report on Thursday, July 16, at 8:00 am EEST. We expect the company's revenue to have grown strongly in Q2, driven primarily by acquisitions and solid organic growth. We also expect the operating result to have improved significantly from the comparison period due to increased volumes, although the ramp-up of new projects may still slightly constrain margin expansion. We expect Scanfil to reiterate its guidance for the current year. In our view, Scanfil's share valuation is currently very neutral, and expectations are realistically reflected in the share price. Our recent extensive report on Scanfil is available here.

Revenue has remained on a strong growth trajectory, driven by acquisitions

We forecast Scanfil's Q2 revenue to have grown by just over 25% year-on-year to 254 MEUR. As in Q1, the clear main driver of growth is inorganic, as the MB and ADCO acquisitions account for almost 75% of the growth in our forecast. However, we also expect organic growth to have continued at a decent pace of around 6%. We expect all regions to have grown organically in Q2, while acquisitions will drive reported figures in the Americas and Central Europe significantly higher. Organic growth has been supported by the ramp-up of new customer projects and strong traction, especially in the Aerospace & Defense segment. Underlying demand in Medtech & Life Science and Energy & Cleantech has remained favorable, while in Industrial, the macroeconomic situation may have been a slight drag, at least on volume growth.

Operating profit has clearly increased with volumes

We expect Scanfil's adjusted EBITA to have grown by 29% in Q2 to 18.4 MEUR. Earnings growth has been primarily driven by strong revenue growth, but we expect the adjusted EBITA margin to have improved slightly to 7.2%. We estimate that profitability was supported by a higher capacity utilization rate, and the profitability of the acquired companies was also slightly better than Scanfil's average. On the other hand, the margin leap has likely been limited by the continued ramp-up of new projects. On the bottom line, earnings have been weighed down by increased PPA depreciation due to acquisitions, financial expenses, and the tax rate. Thus, we forecast Scanfil's reported EPS to have increased to EUR 0.19, slightly slower than the operating profit. We also estimate that cash flow started to recover after the typical working capital commitment in Q1, but volume growth likely kept cash flow weaker than earnings in Q2 as well.

Guidance reiteration forecast, eyes on the demand environment

We expect Scanfil to reiterate its guidance for the current year in connection with the Q2 report, according to which 2026 revenue will be 940–1060 MEUR and adjusted EBITA 64–78 MEUR Our full-year estimates (revenue 993 MEUR and adjusted EBITA 73 MEUR) are fairly close to the mid-points of the guidance ranges. In the report, we will especially monitor the company's comments on customer demand prospects. Inflation and economic growth risks caused by the war in Iran have not yet affected Scanfil's demand. The strong momentum in the defense sector, previous project wins, and the continued positive flow of new projects in Q2 are likely to provide a buffer for the company. We believe Scanfil's valuation is already somewhat elevated in the short term (2026e:  P/E 17x, EV/EBITA 13x), so at the very least, a continued rise in the share price would require increasingly positive comments on organic growth prospects.

Scanfil is an international electronics contract manufacturer, specializing in industrial and B2B customers. Services include manufacturing of end products and components such as PCBs. Manufacturing services are the core of the company, supported by design, supply chain and modernization services. The company operates globally in Europe, America and Asia. Customers are primarily found in the process automation, energy efficiency, green efficiency and medical segments.

Read more on company page

Key Estimate Figures16.06

202526e27e
Revenue797.1993.11,060.2
growth-%2.2 %24.6 %6.8 %
EBIT (adj.)56.472.680.9
EBIT-% (adj.)7.1 %7.3 %7.6 %
EPS (adj.)0.650.780.89
Dividend0.250.270.29
Dividend %2.5 %2.4 %2.5 %
P/E (adj.)15.414.812.9
EV/EBITDA8.58.78.1

Forum discussions

Q2 earnings are just around the corner! The 19 investors who have submitted estimates so far are slightly more cautious than Antti and the broader...
12 hours ago
by Oscar Matheson
4
Here are Antti’s pre-game thoughts ahead of Scanfil’s Q2 results on Thursday, July 16th We expect the company’s revenue to have grown strongly...
19 hours ago
by Sijoittaja-alokas
4
Nordea has updated its thoughts on Scanfil a bit Q2 looks set to be seasonally stronger than Q1 2026. Moreover, the acquisition of MB Elettronica...
7/10/2026, 8:41 AM
by Sijoittaja-alokas
5
Inderes Scanfil tukee TOMRAa Puolan panttijärjestelmän käyttöönotossa - Inderes Scanfil on ollut keskeisessä roolissa TOMRAn pullonpalautusautomaattie...
6/30/2026, 11:06 AM
by Dissidentti
7
Antti has been a busy lead analyst and has produced an extensive report on Scanfil. Like other extensive reports, this one is available for ...
6/17/2026, 7:01 AM
by Sijoittaja-alokas
7
New PRESS release from Scanfil Scanfil is strengthening its collaboration with the AXS division of Bruker’s Life Science & Medtech business....
5/19/2026, 8:49 AM
by Sijoittaja-alokas
5
Hi, it will be available for purchase at Suomalainen Kirjakauppa, and there will also be at least three copies available for borrowing at the...
5/18/2026, 9:37 AM
by Pasi Hiedanpää
4